An observational study in Neovascular Age-related Macular Edema, Diabetic Macular Edema and Choroidal Neovascular Membrane, sponsored by Wenbin Wei. Status unknown at 1 site in China. Open to participants aged 35 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-03.
Sponsored by Wenbin Wei · Observational
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
291 studies on the registry are indexed under Retinal Vein Occlusion; 29 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 126 across 65 observational studies indexed under Retinal Vein Occlusion.
Browse Retinal Vein Occlusion studies →This is the only study on the registry with Wenbin Wei as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with new-onset and recurrent Neovascular age-related macular edema.
Drug: Ranibizumab · Drug: Aflibercept · Drug: Conbercept
Patients with new-onset and recurrent diabetic macula edema
Drug: Ranibizumab · Drug: Aflibercept · Drug: Conbercept
Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
Drug: Ranibizumab · Drug: Aflibercept · Drug: Conbercept
Patients with new-onset and recurrent retinal vein occlusions
Drug: Ranibizumab
Patients with new-onset and recurrent choroidal neovascularization
Drug: Ranibizumab · Drug: Aflibercept · Drug: Conbercept
Ranibizumab 0.5mg/0.05ml intravitreal injection
Aflibercept 2.0mg/0.05ml intravitreal injection
Conbercept 0.5mg/0.05ml intravitreal injection
Visual acuity
LogMAR visual acuity
Time frame: 1 year
Central subfield thickness
he central subfield is defined as the circular area 1 mm in diameter centered around the center point of the fovea
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.